Notice: Function _load_textdomain_just_in_time was called incorrectly. Translation loading for the wordpress-seo domain was triggered too early. This is usually an indicator for some code in the plugin or theme running too early. Translations should be loaded at the init action or later. Please see Debugging in WordPress for more information. (This message was added in version 6.7.0.) in /var/www/html/wp-includes/functions.php on line 6260 Financial Report: Teva 1Q | Contract Pharma

What are you searching for?

Sign in
Breaking News, Financial News

Financial Report: Teva 1Q

Exchange rates impact earnings

Author Image

By: Kristin Brooks

Managing Editor, Contract Pharma

Teva

1Q Revenues: $2.6 billion (+9%)

1Q Earnings: $444 million (-40%)

Comments: Generic revenues were $2.6 billion, up 9%. U.S. revenues of $1.4 billion, up 37% mainly from the launch of esomeprazole (a generic of Nexium). European revenues were $680 million, down 17% mainly from the company’s strategy of pursuing sustainable business in the region, with significant decreases in Spain and France, offset by increases in Italy and Germany. ROW revenues were $502 million, down 6%. API sales to third parties were $157 million, down 12%. Specialty medicines revenues were $2.0 billion, down 7% primarily due to lower sales of Copaxone, which were partially offset by higher revenues of respiratory products. U.S. specialty medicines revenues were $1.5 billion, down 3%, European revenues were $405 million, a decrease of 16%. ROW sales were $72 million, down 29%.

Add us as a preferred source on Google

Get the latest Contract Pharma news, insights and analysis in your Google Search and AI experiences.

Add Contract Pharma as a preferred source on Google (opens in a new tab)

Keep Up With Our Content. Subscribe To Contract Pharma Newsletters